Compare TBLA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | WGS |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | 2000 | 1300 |
| Industry | Computer Software: Programming Data Processing | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | N/A | N/A |
| Metric | TBLA | WGS |
|---|---|---|
| Price | $4.95 | $60.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.00 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 2.7M | 647.3K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | $29.98 |
| Revenue Next Year | $5.25 | $25.92 |
| P/E Ratio | ★ $42.36 | $1,251.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $32.21 |
| 52 Week High | $5.71 | $170.87 |
| Indicator | TBLA | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 47.87 |
| Support Level | $3.94 | $55.76 |
| Resistance Level | $5.18 | $63.31 |
| Average True Range (ATR) | 0.18 | 4.10 |
| MACD | -0.09 | -0.95 |
| Stochastic Oscillator | 24.46 | 21.77 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.